Work

Abstract PD10-07: Efficacy of mutant-selective PI3Kα inhibitor RLY-2608 in combination with fulvestrant in patient (pt) subset populations, including pts with PIK3CA-mutant HR+/HER2- advanced breast cancer (BC) pre-treated with fulvestrant or other SERD

Year: 2026
Type: conference-abstract
Language: English
Field: Medicine
Open Access status: closed
OpenAlex ID: W7129257614
Cites:
Cited by:
Related to: